4D Molecular Therapeutics (FDMT) Non-Current Assets (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Non-Current Assets data on file, last reported at $107.5 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $107.5 million, down 41.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $543.1 million (up 15.7% YoY), and the FY2025 annual result was $153.6 million, up 22.42% from the prior year.
• Non-Current Assets eased to $107.5 million in Q1 2026 per FDMT's latest filing, from $153.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $183.2 million in Q1 2025 and troughed at $33.4 million in Q3 2023.
• A 5-year average of $87.2 million and a median of $81.9 million in 2022 frame the typical range for Non-Current Assets.
• On a YoY basis, Non-Current Assets climbed as much as 1358.74% in 2022 and fell as far as 57.48% in 2022.
• A 5-year view of Non-Current Assets shows it stood at $41.3 million in 2022, then grew by 4.76% to $43.3 million in 2023, then soared by 189.71% to $125.5 million in 2024, then advanced by 22.42% to $153.6 million in 2025, then decreased by 29.98% to $107.5 million in 2026.
• Business Quant data shows FDMT's Non-Current Assets at $107.5 million in Q1 2026, $153.6 million in Q4 2025, and $111.6 million in Q3 2025.